NCT01531153View on ClinicalTrials.gov

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

NACompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Addiction
Interventions
DRUG

Galantamine

8mg or 16mg

DRUG

Placebo

Placebo dose.

Trial Locations (1)

06516

Department of Veterans Affairs, West Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT01531153 - Cognitive Enhancement as a Target for Cocaine Pharmacotherapy | Biotech Hunter | Biotech Hunter